Evidence map›Paper›PMID 32900848›Full record

ArticleThe Journal of biological chemistry2020

Cholesterol sensing by CD81 is important for hepatitis C virus entry.

Machaela Palor, Lenka Stejskal, Piya Mandal, Annasara Lenman, María Pía Alberione, Jared Kirui, Rebecca Moeller, Stefan Ebner, Felix Meissner, Gisa Gerold and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. The molecular mechanism of CD81 antibody inhibition of metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  10. Review
  11. Pseudotyped Virus for Flaviviridae.Advances in experimental medicine and biology · 2023
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Machaela PalorInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College, London, United Kingdom.
Lenka StejskalInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College, London, United Kingdom; Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom.
Piya MandalInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College, London, United Kingdom.
Annasara LenmanDepartment of Clinical Microbiology, Virology & Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden; Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany.
María Pía AlberioneInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany.
Jared KiruiInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany.
Rebecca MoellerInstitute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany.
Stefan EbnerExperimental Systems Immunology, Max Planck Institute of Biochemistry, Martinsried, Germany.
Felix MeissnerExperimental Systems Immunology, Max Planck Institute of Biochemistry, Martinsried, Germany; Institute of Innate Immunity, Department of Systems Immunology and Proteomics, Medical Faculty, University of Bonn, Bonn, Germany.
Gisa GeroldDepartment of Clinical Microbiology, Virology & Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden; Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany; Department of Physiological Chemistry, University of Veterinary Medicine Hannover, Hannover, Germany.
Adrian J ShepherdInstitute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom.
Joe GroveInstitute of Immunity and Transplantation, Division of Infection and Immunity, University College, London, United Kingdom. Electronic address: j.grove@ucl.ac.uk.
Centre for Immunity, Infection and Evolution · GBHelmholtz Centre for Infection Research · DEInstitute of Structural and Molecular Biology · GBMax Planck Institute of Biochemistry · DEUniversity of Bonn · DEUniversity of Veterinary Medicine Hannover, Foundation · DE

Funding

Wellcome TrustWellcome Trust 107653/Z/15/ZWellcome Trust 109162/Z/15/Z
6 · The paper itself

Abstract

CD81 plays a central role in a variety of physiological and pathological processes. Recent structural analysis of CD81 indicates that it contains an intramembrane cholesterol-binding pocket and that interaction with cholesterol may regulate a conformational switch in the large extracellular domain of CD81. Therefore, CD81 possesses a potential cholesterol-sensing mechanism; however, its relevance for protein function is thus far unknown. In this study we investigate CD81 cholesterol sensing in the context of its activity as a receptor for hepatitis C virus (HCV). Structure-led mutagenesis of the cholesterol-binding pocket reduced CD81-cholesterol association but had disparate effects on HCV entry, both reducing and enhancing CD81 receptor activity. We reasoned that this could be explained by alterations in the consequences of cholesterol binding. To investigate this further we performed molecular dynamic simulations of CD81 with and without cholesterol; this identified a potential allosteric mechanism by which cholesterol binding regulates the conformation of CD81. To test this, we designed further mutations to force CD81 into either the open (cholesterol-unbound) or closed (cholesterol-bound) conformation. The open mutant of CD81 exhibited reduced HCV receptor activity, whereas the closed mutant enhanced activity. These data are consistent with cholesterol sensing switching CD81 between a receptor active and inactive state. CD81 interactome analysis also suggests that conformational switching may modulate the assembly of CD81-partner protein networks. This work furthers our understanding of the molecular mechanism of CD81 cholesterol sensing, how this relates to HCV entry, and CD81's function as a molecular scaffold; these insights are relevant to CD81's varied roles in both health and disease.

Indexed as

Virus InternalizationAnimalsCell LineCholesterolCricetinaeHepacivirusHepatitis CHumansMiceMutagenesis, Site-DirectedProtein Structural ElementsReceptors, VirusTetraspanin 28CD81 protein, humanCholesterolReceptors, VirusTetraspanin 28cholesterol-binding proteinhepatitis C virus (HCV)molecular dynamicsplasma membranetetraspaninvirus entry

Identifiers

PMID32900848
PMCPMC7863897
OpenAlexW3084306916

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.